Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac<sup>®</sup> in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac<sup>®</sup> in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa

For more than a century, epidemic meningococcal disease mainly caused by serogroup A <i>Neisseria meningitidis</i> has been an important public health problem in sub-Saharan Africa. To address this problem, an affordable meningococcal serogroup A conjugate vaccine, MenAfriVac<sup>®...

Full description

Bibliographic Details
Main Author:	Simonetta Viviani
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Vaccines
Subjects:	conjugate meningococcal vaccine <i>Neisseria meningitidis</i> serogroup A efficacy effectiveness meningitis epidemic sub-Saharan Africa
Online Access:	https://www.mdpi.com/2076-393X/10/4/617

Similar Items

Serogroup B Invasive Meningococcal Disease in Older Adults Identified by Genomic Surveillance, England, 2022–2023
by: Emily Loud, et al.
Published: (2024-05-01)

Epidemiology of Invasive Meningococcal Disease in Colombia: A Retrospective Surveillance Database Analysis
by: Wilfrido Coronell-Rodriguez, et al.
Published: (2023-11-01)

Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps
by: F. Marc LaForce, et al.
Published: (2018-05-01)

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines
by: Rodolfo Villena, et al.
Published: (2018-05-01)

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature
by: Paul Balmer, et al.
Published: (2018-05-01)

Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges
by: Mustapha M. Mustapha, et al.
Published: (2018-05-01)

A critical analysis of serogroup B meningococcal disease burden in Brazil (2001–2015): implications for public health decisions
by: Luciana Andrea Digieri Chicuto, et al.
Published: (2020-08-01)

The attitudes, behaviors, and knowledge of healthcare professionals towards the diagnosis, treatment, and prevention of bacterial meningitis in Turkey
by: Meltem Dinleyici, et al.
Published: (2019-01-01)

Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
by: Arianna Neri, et al.
Published: (2022-05-01)

Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil
by: David E Barroso, et al.
Published: (2007-09-01)

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations
by: Reinaldo Acevedo, et al.
Published: (2019-01-01)

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection
by: Ray Borrow, et al.
Published: (2017-04-01)

An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
by: Asmaa Alrobai, et al.
Published: (2021-12-01)

Handbook of meningococcal disease : infection biology, vaccination, clinical management /
by: Frosch, Matthias, et al.
Published: (2006)

Developing a Novel Murine Meningococcal Meningitis Model Using a Capsule-Null Bacterial Strain
by: Viorela-I. Caracoti, et al.
Published: (2024-05-01)

Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVacR)
by: Prasad S. Kulkarni, et al.
Published: (2018-05-01)

Meningococcal B vaccine (4CMenB): the journey from research to real world experience
by: Rino Rappuoli, et al.
Published: (2018-12-01)

The important lessons lurking in the history of meningococcal epidemiology
by: Ray Borrow, et al.
Published: (2024-12-01)

Microbiological and Serological Evaluation of the Meningitis Outbreak in a Community Center in Isfahan Province, Iran, during the Years 2016-2017
by: Reza Khadivi, et al.
Published: (2018-04-01)

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study
by: Nan-Chang Chiu, et al.
Published: (2018-05-01)

A severe course of serogroup W meningococcemia in a patient with infantile nephropathic cystinosis
by: Gurkan Bozan, et al.
Published: (2020-11-01)

Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil
by: Lara Evellyn do Macedo, et al.
Published: (2018-05-01)

Vaccines against Meningococcal Diseases
by: Mariagrazia Pizza, et al.
Published: (2020-10-01)

Importance of circulating antibodies in protection against meningococcal disease
by: Kim S. Erlich, et al.
Published: (2012-08-01)

Meningococcal infections among refugees and immigrants: silent threats of past, present and future
by: Ener Cagri Dinleyici, et al.
Published: (2020-11-01)

Herd Protection against Meningococcal Disease through Vaccination
by: Stephen A. Clark, et al.
Published: (2020-10-01)

A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control
by: Yih-Ling Tzeng, et al.
Published: (2021-03-01)

Emergence of invasive meningococcal disease during Hajj pilgrimage – vigilance and preparedness, in the post-pandemic year
by: Jaffar A. Al-Tawfiq, et al.
Published: (2024-08-01)

Primary meningococcal conjunctivitis in an adult patient
by: Pushpinder Kanda, et al.
Published: (2023-01-01)

Meningococcal C Disease Outbreak Caused by Multidrug-Resistant Neisseria meningitidis, Fiji
by: Aneley Getahun Strobel, et al.
Published: (2025-01-01)

Detection of Novel US Neisseria meningitidis Urethritis Clade Subtypes in Japan
by: Hideyuki Takahashi, et al.
Published: (2023-11-01)

Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
by: Federico Martinón-Torres, et al.
Published: (2019-12-01)

Antibiotic Sensitivity of <i>Neisseria meningitidis</i> Isolated From Patients with Generalized Forms of Meningococcal Infection and From Healthy Carriers
by: E. A. MARTENS, et al.
Published: (2022-09-01)

Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines
by: Leonardo Terranova, et al.
Published: (2018-05-01)

Meningococcal vaccines in China
by: Yinghua Xu, et al.
Published: (2021-07-01)

Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines
by: Chen Stein-Zamir, et al.
Published: (2019-01-01)

Epidemiological Manifestations of Purulent Bacterial Meningitis in the Russian Federation
by: M. A. Davydenko, et al.
Published: (2024-11-01)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
by: Beatriz P. Quiambao, et al.
Published: (2017-03-01)

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
by: Pavitra Keshavan, et al.
Published: (2018-10-01)

Epidemiological Features of Purulent Bacterial Meningitis in the Russian Federation at the Present Stage
by: M. A. Koroleva, et al.
Published: (2023-09-01)